The two sides plan to jointly develop a new class of drugs
It is learned that Jiangsu Zhengda Fenghai Pharmaceutical (CTFH) and AI drug research and development company Insilico Medicine have signed two AI technology development service contracts, which are complex and difficult to design drugs. The target. It is expected to accelerate the development of the results, especially for the treatment of patients with triple-negative breast cancer. This partnership includes down payment, milestones, and sales performance rewards. The total value of the project is expected to reach $200 million.
Jiangsu Zhengda Fenghai Pharmaceutical (CTFH) is a joint venture established by Zhengda Group and Jiangsu Agricultural Reclamation Group to develop a variety of pharmaceutical preparations and APIs, including new sugars, anti-infectives, and respiratory medicines. Research and development in the fields of digestive, cardiovascular and cerebrovascular, neuropsychiatric, special medicine and anti-tumor. The company has achieved milestones in the development of a new class of drugs.
Insilico Medicine is a company that uses a new generation of artificial intelligence technology for drug discovery. The company has branches in the United States, the United Kingdom, China, Russia, South Korea and Nigeria. Its core artificial intelligence technology is to generate Generative Adversarial Networks (“GAN”) and Reinforcement Learning (“RL”).
In September of this year, Insilico Medicine published a paper in the Nature Biotechnology journal to confirm that AI accelerates drug discovery. ability. With the help of the system of generative tension-enhanced learning GENTRL, it takes only 46 days to verify the animal from the target to the candidate molecule.
A few days ago, the company announced the completion of a $37 million Series B financing, led by Qiming Ventures Investment, F-Prime, Stora Capital, Lilly Asia Fund, Innovation Works, Baidu Ventures, Lanting Investment, BOLD Capital Partners and other investors.
Xia Wenyu, general manager of Jiangsu Zhengda Fenghai Pharmaceutical, said that he is very pleased to establish a partnership with Insilico Medicine, and believes that through cooperation with Insilico Medicine, it will greatly accelerate the speed of drug development and improve efficiency, and will guide enterprises. Apply new drug development methods. Insilico Medicine uses AI to generate new molecules with specific properties, and is the world leader in drug discovery. Through its AI platform, it canAccelerate the drug development process and reduce development costs.